Home > Gastroenterology > Dostarlimab may offer an alternative for dMMR rectal cancer

Dostarlimab may offer an alternative for dMMR rectal cancer

Presented By
Dr Melissa Lumish, Memorial Sloan Kettering Cancer Center, NY, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GI 2022
Trial
Phase 2
Treatment with dostarlimab resulted in a complete response in all patients with deficient mismatch repair (dMMR) locally advanced rectal cancer who completed therapy. This treatment may avoid chemoradiation and surgery in these patients, which are associated with toxicity and morbidity. Although the durability of response needs to be assessed in long-term follow-up, PD-1 inhibition may become a new paradigm for the treatment of dMMR rectal cancer [1]. “The standard approach for locally advanced rectal cancer is total neoadjuvant therapy, including chemoradiation and total mesorectal excision,” said Dr Melissa Lumish (Memorial Sloan Kettering Cancer Center, NY, USA). “Although patients who display a complete response may be offered non-operative management, targeted strategies for molecular subtypes of rectal cancer may further diminish toxicity and morbidity in these patients.” Dr Lumish added that patients with dMMR rectal cancer have a 25% increased risk...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on